{"organizations": [], "uuid": "bdac3880bd973b7f18ebbac4aaff4ea002be8367", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180330.html", "section_title": "Archive News &amp; Video for Friday, 30 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nanobiotix-fy-net-loss-widens-to-2/brief-nanobiotix-fy-net-loss-widens-to-26-1-million-euros-idUSFWN1RC011", "country": "US", "domain_rank": 408, "title": "BRIEF-Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.678, "site_type": "news", "published": "2018-03-30T22:10:00.000+03:00", "replies_count": 0, "uuid": "bdac3880bd973b7f18ebbac4aaff4ea002be8367"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nanobiotix-fy-net-loss-widens-to-2/brief-nanobiotix-fy-net-loss-widens-to-26-1-million-euros-idUSFWN1RC011", "ord_in_thread": 0, "title": "BRIEF-Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros", "locations": [], "entities": {"persons": [{"name": "nanobiotix", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 30 (Reuters) - NANOBIOTIX SA:\n* TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016\n* CASH AVAILABLE AT DECEMBER 31, 2017 AMOUNTS TO EUR 47.2M.\n* FY NET LOSS EUR ‍​26.1 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO\n* 2018 SHOULD BE ANOTHER YEAR OF GROWTH * FY CORE OPERATING LOSS EUR 24.9 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO\n* EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-30T22:10:00.000+03:00", "crawled": "2018-03-31T19:16:04.014+03:00", "highlightTitle": ""}